Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $21.49

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $21.49, but opened at $21.01. Calliditas Therapeutics AB (publ) shares last traded at $21.01, with a volume of 313 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Stock Down 2.2 %

The company has a debt-to-equity ratio of 2.89, a current ratio of 3.13 and a quick ratio of 3.08. The business has a 50-day moving average of $21.78 and a 200-day moving average of $20.24.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. The firm had revenue of $42.45 million during the quarter, compared to the consensus estimate of $36.24 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. During the same period in the prior year, the business earned ($0.01) EPS. As a group, research analysts forecast that Calliditas Therapeutics AB will post 0.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

Large investors have recently modified their holdings of the business. Optiver Holding B.V. acquired a new stake in Calliditas Therapeutics AB (publ) during the 4th quarter valued at $25,000. Deutsche Bank AG boosted its holdings in shares of Calliditas Therapeutics AB (publ) by 26.5% during the first quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock worth $2,170,000 after purchasing an additional 18,978 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Calliditas Therapeutics AB (publ) by 7.6% during the third quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock worth $191,000 after purchasing an additional 886 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock worth $51,000 after buying an additional 3,112 shares during the period. 2.83% of the stock is owned by hedge funds and other institutional investors.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.